Industry Overview

North America women’s health diagnostics market was valued at $7,981.8 million in 2025 and is projected to reach $16,593.9 million by 2035, growing at a CAGR of 7.6% during the forecast period (2026–2035). The North America women’s health diagnostics market maintains a leading position globally as healthcare providers and diagnostic laboratories intensify their focus on preventive care, early detection, and personalized medicine. Growth is supported by widespread adoption of advanced diagnostic technologies, including molecular testing, AI-assisted imaging, and point-of-care solutions, across hospitals, clinics, and diagnostic centers. High awareness levels, favorable reimbursement frameworks, and well-established screening programs for breast, cervical, and reproductive health conditions continue to drive diagnostic utilization. Demand is further strengthened by a rising burden of age-related and chronic diseases among women and increasing emphasis on data-driven clinical decision-making. As regulatory bodies and healthcare organizations prioritize timely and accurate diagnosis, women’s health diagnostics solutions remain essential in improving patient outcomes and supporting cost-efficient care delivery across North America.

Market Dynamics

Strong Emphasis on Early Detection and Preventive Women’s Healthcare

The North America women’s health diagnostics market continues to expand as healthcare providers, diagnostic laboratories, and public health organizations prioritize early detection and preventive care. High awareness levels, routine screening practices for breast and cervical cancer, and widespread adoption of reproductive health testing are driving sustained diagnostic demand. Hospitals and outpatient clinics are increasingly incorporating advanced diagnostic technologies to support accurate and timely clinical decision-making. Research institutions and healthcare networks are also contributing to innovation through clinical validation studies and real-world evidence generation. Favorable reimbursement policies and strong support from government and private payers further reinforce diagnostic utilization. Together, these factors are fueling consistent market growth across the region.

Rapid Adoption of Advanced Diagnostic Technologies and AI-Enabled Solutions

Technological innovation remains a central catalyst in the North America women’s health diagnostics market, with rapid adoption of molecular diagnostics, AI-driven imaging platforms, and point-of-care testing solutions. AI-assisted mammography and ultrasound systems are improving early cancer detection rates while optimizing radiology workflows. Advanced molecular assays and automated laboratory platforms are enabling high-throughput testing with improved sensitivity and faster turnaround times. Cloud-based data integration and digital health platforms are supporting seamless information flow across care settings. Regulatory bodies such as the FDA are increasingly supporting innovation through clear approval pathways for novel diagnostic technologies. As a result, the growing reliance on advanced, data-driven diagnostic solutions is accelerating market expansion across North America.

Market Segmentation

• Based on the application, the market is segmented into breast cancer testing, cervical cancer testing, pregnancy & fertility testing, ovarian cancer testing, infectious disease testing, ultrasound tests, sexually transmitted disease testing, and others.
• Based on the end-user, the market is segmented into diagnostic and imaging centers, hospitals and clinics, and home care.

Breast Cancer Testing Segment to Lead the Market with the Largest Share

The breast cancer testing segment dominates the North America women’s health diagnostics market, driven by high screening penetration, strong awareness levels, and advanced diagnostic infrastructure. Routine mammography, supplemented by molecular and biomarker-based tests, plays a critical role in early detection and personalized treatment planning. The integration of AI-enabled imaging technologies is further improving diagnostic accuracy and workflow efficiency. Favorable reimbursement policies and strong clinical guidelines continue to support widespread adoption of breast cancer diagnostics. As early diagnosis remains central to improving survival outcomes, this segment continues to hold the largest share in the regional market.

Hospitals and Clinics: A Key End-User Segment Driving Market Growth

Hospitals and clinics are the leading end users in the North America women’s health diagnostics market, supported by comprehensive women’s healthcare services and advanced diagnostic capabilities. These settings serve as primary hubs for routine screenings, prenatal care, and cancer diagnostics. Ongoing investments in AI-assisted imaging, laboratory automation, and digital health platforms are enhancing operational efficiency and diagnostic throughput. Additionally, increasing patient demand for preventive care and personalized diagnostics is driving higher test volumes. Together, these factors underscore the dominant role of hospitals and clinics in driving regional market growth.

Regional Outlook

North America women’s health diagnostics market is further divided by countries, including US and Canada.

US Dominates the Market with Major Share

The United States maintains a dominant position in the North America women’s health diagnostics market, supported by advanced healthcare infrastructure, high screening penetration, and strong awareness of preventive women’s healthcare. Routine breast and cervical cancer screening programs, combined with widespread adoption of molecular testing and AI-assisted imaging solutions, are driving sustained diagnostic demand. The presence of leading diagnostic companies, continuous technological innovation, and favorable reimbursement frameworks further strengthen market growth. Healthcare providers across hospitals, clinics, and diagnostic centers are increasingly investing in advanced diagnostic platforms to improve accuracy and workflow efficiency. As emphasis on early detection, personalized care, and data-driven clinical decision-making continues to grow, the US remains a central driver of innovation and market leadership in women’s health diagnostics.

Market Players Outlook

The major companies operating in the North America women’s health diagnostics market include Abbott Laboratories, Danaher Corporation, Hologic, Inc., Quest Diagnostics Incorporated, Thermo Fisher Scientific Inc., among others. Market players are leveraging partnerships, collaborations, mergers, and acquisition strategies for business expansion and innovative product development to maintain their market positioning.

Recent Development

• In June 2025, Hologic, Inc. launched an advanced AI-powered breast imaging and diagnostics platform across the United States and Canada. The solution is designed to improve early breast cancer detection rates while reducing diagnostic variability across clinical settings.
• In April 2025, Abbott Laboratories expanded its women’s health diagnostics portfolio in North America with new molecular and point-of-care assays for sexually transmitted diseases and reproductive health screening. The initiative aims to support faster results and broader access across hospitals, clinics, and outpatient care facilities.

The Report Covers

• Market value data analysis of 2025 and forecast to 2035.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the North America women’s health diagnostics Based on the availability of data, information related to new products and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.